Clinical study of BBM-A101 in knee Osteoarthritis
Latest Information Update: 03 Apr 2025
At a glance
- Drugs BBM A101 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2025 New trial record
- 27 Mar 2025 According to Belief BioMed media release, company announced that it has received National Medical Products Administration (NMPA) clearance of an Investigational New Drug (IND) application for BBM-A101, a gene therapy drug for knee osteoarthritis (KOA).